Lung Cancer Trials Ask AI to find trials
WithdrawnPhase 2NCT06555263
Official study title

Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer

Study summary

A Phase 2 study evaluating STRO-002 in subjects with previously treated advanced or metastatic non-small cell lung cancer expressing FOLR1

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedLuveltamab tazevibulin

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 22, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Withdrawn

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?7 U.S. locations

Locations may change over time.

Who runs it?Sutro Biopharma, Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
Sutro Biopharma, Inc.
Interventions being studied
Drug: Luveltamab tazevibulin
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Metastatic or stage IV→
Study topics
After prior treatment→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologically or cytologically confirmed non-squamous/adenocarcinoma or adenosquamous NSCLC that is either unresectable Stage IIIb/c disease not amenable for definitive chemoradiation, or Stage IV.
  • Age ≥ 18 years
  • ECOG performance status 0 to 1.
  • Received at least 2 but no more than 4 prior lines of systemic therapy for advanced NSCLC
  • Disease progression during or following the most recent systemic anti-cancer therapy.
  • Positive FOLR1 expression per central testing
  • At least 1 measurable target lesion per RECIST 1.1
  • Adequate organ function
Reasons someone may not be able to joinExclusion criteria
  • Prior treatment with a FOLR1- targeting ADCs or with ADCs that contain a tubulin inhibitor
  • Untreated central nervous system metastases
  • Ongoing immunosuppressive therapy, except for treated brain metastases, per criterion above.
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or to antibody-related fusion protein treatment
  • Pre-existing clinically significant ocular disorders, severe chronic obstructive pulmonary disease or asthma, clinically significant cardiac or cerebrovascular disease, or other significant concurrent, uncontrolled medical condition
  • Previous solid organ transplantation
  • Concurrent participation in another therapeutic treatment trial

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • UC San Diego Health - Moores Cancer CenterLa Jolla, California
  • Georgetown University Medical Center - Lombardi Comprehensive Cancer CenterWashington D.C., District of Columbia
  • Florida Cancer Specialists & Research Institute (FCS)Lake Mary, Florida
  • Tampa General Hospital - Cancer Center of South FloridaTampa, Florida
  • HealthPartners Frauenshuh Cancer CenterSaint Louis Park, Minnesota
  • HealthPartners Cancer Center at Regions HospitalSaint Paul, Minnesota
  • Mary Crowley Cancer ResearchDallas, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 22, 2025. Always confirm current availability with the study team.

View original record ↗